GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study

Table 3 Genomic alterations detected in the 15 samples

ID	Mutations detected by NGS
ID	Tumor content (%)	KRAS mutation	Mutant alleles (%)	Mutant alleles normalized for tumor content (%)	HS	GNAS mutation	Mutant alleles (%)	Mutant alleles normalized for tumor content (%)	HS	Other mutations (mutant alleles; normalized for tumor content; HS)	MGMT methylation^a	MET Expression^b	MET amplification^c
1	45	G12C	12	27	54	R201H	16	36	72		No	300	No
2	40	G12D	26	65	130	R201H	24	60	120		Yes	100	No
3	30	WT	–	–	–	WT	–	–	–		No	60	No
4	40	G12D	12	30	60	R201H	11	28	56		No	80	2 % small clusters
5	20	G13D	7	35	70	WT	–	–	–	TP53 R248 W (20 %;100 %; 200)	No	250	>5 signals in < 50 % cells
6	10	G13D	4	40	80	WT	–	–	–		Yes	180	No
7	20	G12D	9	45	90	WT	–	–	–	FGFR3 A257 V (9 %; 45 %; 90) LKB1 P319S (8 %; 40 %; 80)	No	90	No
8	50	G12D	13	26	52	R201C	14	28	56	TP53 R273H(23 %; 46 %; 92) HNF1A R278 W (5 %; 10 %; 20)	No	10	No
9	50	G12D	30	60	120	R201H	15	30	60		Yes	140	No
10	30	G12 V	8	27	54	R201H	3	10	20		No	160	1 % small clusters
11	20	G12 V	18	90	180	WT	–	–	–	TP53 C238F (19 %; 95 %; 190)	No	60	NO
12	10	G12D	1	10	20	R201H	6	60	120		No	90	No
13	35	G12V	5	14	28	R201H	10	29	58		No	90	No
14	80	G12D	23	29	58	R201H	24	30	60		No	60	No
15	30	G12D	4	13	26	WT	–	–	–		No	140	No

^a MGMT methylation status is assessed by methylation-specific Polymerase chain reaction
^b MET expression is assessed by immunohistochemistry and is reported as H-score
^c MET amplification status is assessed by in situ hybridization

ISSN: 1479-5876